Owlstone Medical hiring in UK and at expanded US base
Cambridge breath biopsy pioneer Owlstone Medical has expanded its US operations including establishing a permanent office on the North Carolina Research Triangle Park and is hiring on both sides of the Atlantic.
Owlstone says it was keen to better support its pharmaceutical and academic customers in America by visibly putting down deeper roots while upskilling.
Owlstone’s vision is to save 100,000 lives by realising the enormous healthcare and economic promise of breath-based diagnostics through the development and application of its disease breathalyser.
The key challenges it is working to address are the early detection of disease, including cancer and liver conditions, which can have a profound impact on long-term survival rates; and precision medicine in areas such as asthma and COPD.
In this arena, Owlstone Medical seeks to better understand the progression of disease between individuals and to predict which patients will respond to which therapeutics.
To realise this opportunity the business is focused on providing high value products and services to pharmaceutical and academic clients and developing tests in multi-billion dollar areas of major clinical need.
Owlstone says it has built a world-class US business development team to help drive this effort.
At its North Carolina facility it has established a team of accomplished translational and clinical scientists with vast experience in metabolomics, biochemistry, and the biology that underpins disease.
This group will serve as liaisons to local customers, addressing technical inquiries, offering expert guidance on clinical study design, providing professional report generation, and presenting biological interpretation of study results.
The group will also enable deepening of existing US pharmaceutical and academic partnerships, along with expanding uptake of Owlstone Medical’s services by driving awareness of Breath Biopsy and the value of breath profiling.
Huw Davies, VP of Global Sales at Owlstone Medical, said: “Owlstone Medical’s Research Products and Services are offered through a transparent and efficient process which has been refined over time through our experience working with academic, clinical, and pharmaceutical partners from around the world.
“With the opening of our US office, we are excited to be able to offer enhanced local support as we work with our customers to discover and deploy reliable and clinically relevant biomarkers on breath.”
Dr Robert Mohney, head of Clinical and Translational Science at Owlstone Medical from the US office will be presenting 'Discovery and Clinical Investigation of Non-Invasive Biomarkers using Breath Biopsy®' at 1pm EST / 10am PST on January 27.